BIO2017: Spyryx Biosciences To Present At The 2017 BIO International Convention

Published: Jun 19, 2017

DURHAM, N.C., June 19, 2017 /PRNewswire/ -- Spyryx Biosciences, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics to address severe lung diseases, today announced that President and Chief Executive Officer, John Taylor, will present a corporate overview at the 2017 BIO International Convention at the San Diego Convention Center in San Diego, California, on Tuesday, June 20 from 3:30 PM3:45 PM PDT/6:30 PM 6:45PM EDT.

The BIO International Convention allows for public and private companies to provide formal presentations,request face-to-face meetings with biotech investors and executives,attend educational sessions and engage in networking opportunities.For more information, please visit: http://convention.bio.org/about-bio-convention/

About Spyryx Biosciences
Spyryx Biosciences is a privately held, clinical-stage biopharmaceutical company developing innovative therapeutics to address severe lung diseases. Spyryx's lead clinical candidate, SPX-101, is a novel treatment for cystic fibrosis (CF) that is advancing into Phase 2 in people living with CF. The product has demonstrated a robust ability to restore mucociliary clearance in animal models of the disease and has the potential to improve lung function independent of the disease-causing CFTR mutation. The Spyryx leadership team and scientific staff have extensive experience in the development of respiratory medicines and work closely with a broad group of clinical and scientific experts in the pulmonary field. Spyryx is funded by a first tier syndicate of life science investors, including Canaan Partners, 5AM Ventures and Hatteras Venture Partners. Further information regarding Spyryx Biosciences is available at www.spyryxbio.com.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spyryx-biosciences-to-present-at-the-2017-bio-international-convention-300475556.html

SOURCE Spyryx Biosciences, Inc.

Back to news